entertainment -WSS

entertainment

author：focus 2025-09-29 20:52:29 - browse：5221

Insitro CEO and founder Daphne Koller Neilson Barnard/Getty Images for The New York Times

SAN FRANCISCO — It took only a single, one-hour meeting in a Starbucks to convince venture capitalist Robert Nelsen that he was going to invest in the company being built by machine-learning whiz Daphne Koller. “She’s just an amazing force of nature,” said Nelsen, who invests for ARCH Venture Partners.

Koller’s company, Insitro, in a matter of months raised over $100 million from big-name investors including ARCH, Foresite Capital, Andreessen Horowitz, and the firm that manages Jeff Bezos’ personal VC investments. (Koller refers to Bezos by his first name.) Now, it’s time for the next step. On Tuesday, the giant drug maker Gilead Sciences said it would pay Insitro $15 million — and up to $1 billion more down the line if it meets certain goals — for help in developing drugs to treat a common liver disease. It is the South San Francisco-based company’s first deal with a drug maker, and offers a test of whether artificial intelligence can remake drug development.

The very nature of the financials emphasize the exciting but risky reality: The technology has great promise, but nothing is guaranteed.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： Take antibiotics after sex, CDC recommends for certain risk groups

knowledge

WSS

U.K. decision on ALS drug has neurologists, advocates up in arms

U.K. decision on ALS drug has neurologists, advocates up in arms

Mass General Brigham physicians react to latest merger step

Drug companies' payments and gifts affect physicians' prescribing

Eli Lilly’s Zepbound improved liver scarring in mid

Depression: FDA OKs Otsuka Pharmaceuticals digital therapeutic

Wikipedia

entertainment

leisure time

Wildfire smoke exposes gaps in outdoor worker protections

Senators tussle over abortion against the backdrop of a presidential campaign

Novavax promises a turnaround & Lilly roils the obesity market

CMS got Medicare Advantage quality rating wrong, judge rules

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

STAT wants to know your pick for a great summer read or listen

Psychedelics group wrestles with new pharma identity

Oral obesity drug from Viking Therapeutics hits key early target

Activists slam private health insurers over coverage restrictions

Young boy dies in trial for Pfizer Duchenne gene therapy

leisure time

Medicare Advantage's lean provider networks lead CMS complaints

Anthony Fauci pushes back on GOP claims during Covid hearing

A new initiative will help leaders fight the next pandemic

UnitedHealth, in a surprise, takes aim at Steward’s physician group

Data don't support strong claims for Covid

CMS got Medicare Advantage quality rating wrong, judge rules

hotspot

Wikipedia

knowledge

hotspot